First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).
Shaan Dudani(William Osler Health System), Daniel Yick Chin Heng(University of Calgary), Camillo Porta(University of Pavia), Aaron R. Hansen(Princess Margaret Cancer Centre), Ziad Bakouny(Dana-Farber Cancer Institute), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Connor Wells(Queen Mary University of London), Sumanta K. Pal(City of Hope), Toni K. Choueiri(Harvard University), Frede Donskov(Aarhus University Hospital), Jeffrey Graham(University of Calgary), Ulka N. Vaishampayan(University of Michigan), Marco Iafolla(University of Alberta), Lori Wood(Dalhousie University), Takeshi Yuasa(Japanese Foundation For Cancer Research), Nazlı Dizman(City Of Hope National Medical Center), Flora Yan(Temple University), Guillermo de Velasco(Hospital Universitario 12 De Octubre), Georg A. Bjarnason(Sunnybrook Health Science Centre), Elizabeth Liow(Peter MacCallum Cancer Centre)
Cited by 1
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k